Moleculin (NASDAQ: $MBRX) is a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant cancers and viruses.
We are advancing our three core technologies for multiple indications and remain dedicated to driving each of the programs forward.
$MBRX
#Oncology
#Viruses
We are committed to solving the toughest challenges in highly resistant cancers and viruses. Through our extensive network of world-renowned research organizations, we aim to develop better treatments that can make a real impact in people’s lives.
#Oncology
#Viruses
$MBRX
The FDA has granted Orphan Drug Designation to Annamycin for treatment of soft tissue sarcomas. This is now the second Orphan Drug designation for Annamycin.
Today we announced positive interim results in a pediatric brain tumor Phase 1 clinical trial at Emory University. View press release for more details.
We are pleased to have received clearance to initiate our Phase 1b/2 clinical trial of Annamycin in the first of several planned U.S. clinical sites for the treatment of
#SarcomaLungMetastases
.
$MBRX
#LungMets
#Sarcoma
We have entered into an agreement with Sterling Pharma USA LLC for US production of WP1122 to support expanded development efforts in preparation for submitting a request to the FDA for IND status for WP1122 for the potential treatment of COVID-19.
Our CEO and Chairman, Walter Klemp, provides an overview of a recent press release announcing we received MHRA authorization to commence a Phase 1a clinical trial of WP1122 for the potential treatment of
#COVID19
.
#COVID_19
#SARSCoV2
$MBRX
In recognition of
#GlioblastomaAwarenessDay
, we would like to shine a light on this complex, treatment-resistant, and deadly type of brain cancer. Learn more about
#GBM
at .
$MBRX
#Glioblastoma
We successfully completed a pre-IND meeting with the FDA regarding the development plan for Annamycin and intend to file an IND using Annamycin for the treatment of soft tissue sarcomas with lung metastases by year-end.
Moleculin to present animal data demonstrating highly improved activity of Annamycin against acute myeloid leukemia in combination with Ara-C at the 62nd Annual Meeting & Exposition of the American Society for Hematology.
Walter Klemp, President and CEO of Moleculin, speaks to the Company's rebranding and continued commitment to solving some of the toughest challenges in highly resistant cancers and viruses.
$MBRX
#STSLungMets
#Sarcoma
#AcuteMyeloidLeukemia
#Oncology
The FDA has granted our request for a Pre-IND Meeting to provide guidance regarding our plans to study drug candidate WP1122 in a clinical trial for patients with COVID-19. Additional information can be found in today’s press release.
We have entered into an agreement with the University of Campinas in São Paulo, Brazil to further enable collaboration into our research on the anti-viral capabilities of our drug candidate WP1122, specifically for the coronavirus.
Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19.
$MBRX
#COVID19
#SARSCoV2
We have entered into an agreement with ImQuest Biosciences to expand in vitro and in vivo testing of WP1122, our lead drug candidate for the treatment of COVID-19.
Results of a repeated round of in vitro testing received on June 1, 2020, confirm that WP1122 has an antiviral effect on Human Coronavirus 229E ("HCoV-229E"), a surrogate of SARS-CoV-2, the virus responsible for COVID-19.
We are pleased to announce that our proof of concept clinical trial to evaluate our p-STAT3 inhibitor, WP1220, for the topical treatment of Cutaneous T-Cell Lymphoma (CTCL) has reached full enrollment.
Our Chairman and Chief Executive Officer, Wally Klemp, will participate on the COVID-19 panel at Maxim Group's Infectious Disease Virtual Conference on May 5, 2020.
Today we entered into an agreement with UTMB to conduct research on our patented portfolio of molecular inhibitors, including drug candidate, WP1122, for antiviral properties against a range of viruses, including Coronavirus.
Today at 4:30PM ET our Chairman & CEO, Wally Klemp, will host a web-based conference call to discuss the recent discovery that the active compound in WP1122 reduces in vitro replication of SARS-CoV-2 by 100%. Click below for more details.
Emory University Clinical Trial Review Committee to move forward with an Investigator Initiated clinical trial of our immune-stimulating/transcriptional-modulator, WP1066, for the treatment of pediatric brain tumors. $MBRX
Today we announced that recruiting has begun and the first patient has been enrolled in the Emory University Phase 1 clinical trial of WP1066 for the treatment of brain tumors in children.
Today we announced the filing of new patents covering the production and reconstitution of Annamycin, which is currently in two clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML). $mbrx
Today we announced the expansion of Annamycin production commitments in response to positive AML clinical trial activity and the potential expansion of indications for use to include lung-localized tumors. $MBRX